Update on duloxetine for the management of stress urinary incontinence

Clinical Interventions in Aging

Volumn 4, Issue 1, 2009, Pages 25-30

  Basu, Maya ^a   Duckett, Jonathan R A ^a  

^a MEDWAY MARITIME HOSPITAL   (United Kingdom)

Author keywords

Duloxetine; Overactive bladder; Stress urinary incontinence

Indexed keywords

DULOXETINE; NORADRENALIN; PLACEBO; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; VENLAFAXINE;

BLADDER CAPACITY; BLADDER SPHINCTER; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HUMAN; HYPERHIDROSIS; MUSCLE CONTRACTION; NAUSEA; NEUROMODULATION; NONHUMAN; OVERACTIVE BLADDER; PELVIC FLOOR MUSCLE TRAINING; QUALITY OF LIFE; REVIEW; STRESS INCONTINENCE; URETHRA; XEROSTOMIA;

DEPRESSION; FEMALE; GREAT BRITAIN; HUMANS; NERVOUS SYSTEM; SEROTONIN UPTAKE INHIBITORS; THIOPHENES; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE, STRESS; URINARY TRACT;

EID: 66249099172     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Fultz N, Burgio K, Diokno A, Kinchen K, Odenchain R, Bump R. Burden of stress urinary incontinence for community dwelling women. Am J Obstet Gynecol. 2003;189:1275-1282.
2. Rogers G, Villarreal A, Kammerer-Doak D, Qualls C. Sexual function in women with and without urinary incontinence and/or pelvic organ prolapse. Int Urogynecol J Pelvic Floor Dysfunct. 2001;12:361-365.
3. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61:37-49.
4. Hunskaar S, Lose G, Sykes D, Voss S. The prevalence of urinary incontinence in women in four European countries. BJU Int. 2004;93:324-330.
5. Subak L, Brown J, Kraus S, et al. The "costs" of urinary incontinence for women. Obstet Gynecol. 2006;107:908-916.
6. Ward K, Hilton P. UK and Ireland TVT Trial Group. Tension free vaginal tape versus colposuspension for primary urodynamic stress incontinence: 5 year follow up. BJOG. 2008;115:226-233.
7. Melville J, Delaney K, Newton K, Katon W. Incontinence severity and major depression in incontinent women. Obstet Gynecol. 2005;106:585-592.
8. Fields H, Heinricher M, Mason P. Neurotransmitters in nociceptive modulatory circuits. Annu Rev Neurosci. 1991;14:219-245.
9. Ren K, Dubner R. Descending modulation in persistent pain: an update. Pain. 2002;100:1-6.
10. Stahl S. Basic psychopharmacology of antidepressants, part I: antidepressants have seven distinct mechanisms of action. J Clin Psychiatry. 1998;59(suppl 4):5-14.
11. Detke M, Lu Y, Goldstein D, et al. Duloxetine 60 mg once daily for major depressive disorder: a randomised double-blind placebo controlled trial. J Clin Psychiatry. 2002;63:308-315.
12. Goldstein D, Mallinckrodt C, Lu Y, Demitrack M. Duloxetine in the treatment of major depressive disorder: a double blind clinical trial. J Clin Psychiatry. 2002;63:225-231.
13. Raskin J, Goldstein D, Mallinckrodt C, Ferguson M. Duloxetine in the long term treatment of major depressive disorder. J Clin Psychiatry. 2003;64:1237-1244.
14. Raskin J, Pritchett Y, Wang F, et al. A double blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005;6:346-356.
15. Pajoncini C, Constantini F, Guercini F, Bini V, Porena M. Clinical and urodynamic features of intrinsic sphincter deficiency. Neurourol Urodyn. 2003;22:264-268.
16. Fleischmann N, Flisser A, Blaivas J, Panagopoulos G. Sphincteric urinary incontinence: relationship of vesical leak point pressure, urethral mobility and severity of incontinence. J Urol. 2003;169:999-1002.
17. Pierce L, Reyes M, Thor K, et al. Innervation of the levator ani muscles in the female squirrel monkey. Am J Obstet Gynecol. 2003;188:1141-1147.
18. Barber M, Bremer R, Thor K, Dolber P, Kuehl T, Coates K. Innervation of the female levator ani muscles. Am J Obstet Gynecol. 2002;187:64-71.
19. Michel M, Peters S. Role of serotonin and noradrenaline in stress urinary incontinence. BJU Int. 2004;94(Suppl 1):23-30.
20. Espey M, Downie J. Serotonergic modulation of cat bladder function before and after spinal transection. Eur J Pharmacol. 1995;221:167-117.
21. Thor K, Katofiasc M. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anaesthetized female cat. J Pharmacol Exp Ther. 1995;274:1014-1024.
22. Boy S, Reitz A, Wirth B, Karsenty G, Knapp P, Schurch B. Facilitatory neuromodulative effect of duloxetine on urethral sphincter motor neurones in healthy females. Eur Urol Suppl. 2005;4:253. Abstract 998.
23. Bump R, Benson J, Brubaker L, et al. Biomechanical and electrophysiological effects of duloxetine in women with stress urinary incontinence. Neurourol Urodyn. 2004;23:abstract 269.
24. Athanasiou S, Chaliha C, Digesu A, et al. The effects of duloxetine on urethral function and sphincter morphology. Int Urogynecol J Pelvic Floor Dysfunct. 2007;18:763-767.
25. Duckett J, Patil A, Aggarwal I. The effect of duloxetine on urethral sphincter morphology. Ultrasound Obstet Gynecol. 2008;31:206-209.
26. Norton P, Zinner N, Yalcin I, Bump R, for the Duloxetine Urinary Incontinence Study Group. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol. 2002;187:40-48.
27. Dmochowski R, Miklos J, Norton P, Zinner N, Yalcin I, Bump R, for the Duloxetine Urinary Incontinence Study Group. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol. 2003;170:1259-1263.
28. van Kerrebroeck P, Abrams P, Lange R, et al. for the Duloxetine Urinary Incontinence Study Group. Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. BJOG. 2004;111:249-257.
29. Millard R, Moore K, Rencken R, Yalcin I, Bump R, for the Duloxetine Urinary Incontinence Study Group. Duloxetine versus placebo in the treatment of stress urinary incontinence: a four continent randomized clinical trial. BJU Int. 2004;93:311-318.
30. Ghoniem G, Schagen van Leeuwen J, Elser D, et al. A randomized controlled trial of duloxetine alone, pelvic fl oor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. J Urol. 2005;173:1647-1653.
31. Perucchini D, DeLancey J, Ashton-Miller J, Galecki A, Scheer G. Age effects on urethral striated muscle II: anatomic location of muscle loss. Am J Obstet Gynecol. 2002;186:356-360.
32. Viktrup L, Yalcin I. Duloxetine treatment of stress urinary incontinence in women: effects of demographics, obesity, chronic lung disease, hypoestrogenism, diabetes mellitus, and depression on efficacy. Eur J Obstet Gynecol Reprod Biol. 2007;133:105-113.
33. Schagen van Leeuwen J, Lange R, Jonasson A, Chen W, Viktrup L. Efficacy and safety of duloxetine in elderly women with stress urinary incontinence or stress-predominant mixed urinary incontinence. Maturitas. 2008;60:138-147.
34. Duckett J, Vella M, Kavakuntla G, Basu M. Tolerability and effi cacy of duloxetine in a non-trial situation. BJOG. 2007;114:543-547.
35. Cardozo L, Drutz H, Baygani S, Bump R. Pharmacological treatment of women awaiting surgery for stress incontinence. Obstet Gynecol. 2004;104:511-519.
36. Vella M, Duckett J, Basu M. Duloxetine one year on: the long term outcome of a cohort of women prescribed duloxetine. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19:961-964.
37. Steers W, Herschorn S, Kreder K, et al. Duloxetine OAB Study Group. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU Int. 2007;100:337-345.
38. Bent A, Gousse A, Hendrix S, et al. Duloxetine compared with placebo for the treatment of women with mixed urinary incontinence. Neurourol Urodyn. 2008;27:212-221.
39. Bae J, Moon D, Lee J. The effects of a selective noradrenaline reuptake inhibitor on the urethra: an in vitro and in vivo study. BJU Int. 2001;88:771-775.
40. Erdinc A, Gurates B, Celik H, Polat A, Kumru S, Sinsek M. The effi cacy of venlafaxine in treatment of women with stress urinary incontinence. Arch Gynecol Obstet. 2008;Jul 16. Epub ahead of print.
41. National Collaborating Centre for Women's and Children's Health. NICE Clinical Guideline Number 40: The management of urinary incontinence in women. National Institute for Health and Clinical Excellence 2006, London.
42. Castro-Diaz D, Palma P, Bouchard C, et al. Duloxetine Dose Escalation Study Group. Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2007;18:919-929.
43. Robinson D, Anders K, Cardozo L, et al. What do women want: interpretation of the concept of cure. J Pelvic Med Surg. 2003;9:273-277.